Press release

# FDA grants orphan-drug designation to ZENEO® Midazolam

Dijon, 1 February 2018

**CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing a portfolio of innovative combined drugs for use in emergency situations,** has crossed a major milestone in the development of its drug portfolio.

The Food and Drug Administration (FDA)[1] has granted ZENEO® Midazolam orphan-drug designation for "treatment of status epilepticus" (epileptic seizure lasting more than five minutes). Crossject confirms the objective of filing a marketing approval application for ZENEO® Midazolam in 2019, in the USA and in Europe.

Epilepsy is a neurological condition that affects 50 million people worldwide[2]. Epileptic seizures can have serious neurological and physical consequences. Its ease of use means that ZENEO® Midazolam can help stop seizures quickly, before the patient arrives at hospital, making it a major advance in saving lives.

Patrick Alexandre, Chairman of the Management Board of Crossject, said: *"Obtaining orphan-drug status for ZENEO® Midazolam in the United States is a real success for our pharmaceutical development teams. It improves our international visibility, especially with pharmaceutical companies interested in our products. I would therefore like to extend special thanks to our teams: this excellent news rewards their efforts."*

[1] FDA: the American body that approves, among other things, the marketing of medicines in the United States
[2] Source: World Health Organization

**Next release:**

20 March 2018 (after trading): 2017 annual results

## Contacts:

Crossject
Patrick Alexandre
info@crossject.com

Relations investisseurs
CM-CIC Market Solutions
Catherine Couanau +33 (0) 1 53 48 81 97
catherine.couanau@cmcic.fr

Relations presse
Buzz & Compagnie
Mélanie Voisard +33 (0)3 80 43 54 89
melanie.voisard@buzzetcompagnie.com
Audrey Lachat +33 (0)3 80 43 54 89
audrey.lachat@buzzetcompagnie.com

## About CROSSJECT · www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ) is a specialty pharma company developing a portfolio of drugs for use in emergency situations (severe migraines, epilepsy, temporary paralysis, anaphylactic shock, overdoses, acute asthma attacks, etc.). With Zeneo®, its patented needle-free injection system, Crossject provides an efficient response to emergencies by enabling the simple self-administration of drugs. Crossject has been listed on the Euronext Growth market since February 2014.

## Disclaimer

This press release may contain forward-looking information. Such information constitutes neither a trend nor an objective, and cannot be seen as a forecast of results or any other performance indicator. This information is inherently subject to risks and uncertainties, which in some cases may be beyond the control of the Company, especially as relating to an R&D process. A more detailed description of these risks and uncertainties can be found in the Company's annual financial report, available on its website (www.crossject.com).

**Translation for information purposes only. In case of discrepancy between the French and English versions of this press release, only the French version should be deemed valid.**